Poland

Key Insights

1
No psychedelic therapy is approved in Poland; legal patient access is limited to standard care, with ketamine and esketamine available only through conventional medical use.
2
Poland logs 19 psychedelic trials, 4 active; psilocybin and ketamine dominate the active pipeline, alongside LSD and placebo.
3
Poland’s standout contribution is academic, not commercial: the field is concentrated in one research organisation, echoing its broader strength in specialised clinical science.
4
Momentum hinges on a small, focused network and 2025-era academic work from Polish centres; if regulations loosen, the 4 active trials could scale quickly.

Medical Only (Private)

Reimbursed Care Access

Poland has a restrictive national drug-control framework that places classic psychedelics (psilocybin, DMT, mescaline, MDMA and many tryptamines/2C-derivatives) in controlled lists, with authorised medical use limited to clinical research or tightly regulated exceptions. Esketamine (Spravato) is the single psychedelic-derived medicine implemented into a reimbursed drug‑program (B.147) for treatment‑resistant depression; ketamine is legally available for anaesthesia and appears in private/off‑label psychiatric services but is not reimbursed for routine antidepressant indications. Most other psychedelics owe possible access only to approved clinical trials or are otherwise prohibited outside research/authorised use under the Act on Counteracting Drug Addiction and the Minister of Health regulation.

Full guide →